/

HCWB

HCW Biologics Inc.Pre-market

1.26−0.22 −14.86%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delay

Open

1.30

Prev close

1.48

Day range

1.251.45

52-week range

1.2526.85

Volume

2.13M5.56×

Mkt cap

2.82M

P/E ttm

—

Fwd P/E

-2.29

EPS ttm

-19.84

Div yield

0.00%

Earnings

—

From 52w high

−95.31%

Price Chart

Yahoo Finance · delayed

HCWBOct 13, 2026O 1.30H 1.45L 1.25C 1.26−0.22 (−14.86%)Vol 2.13M

SMA 502.38
SMA 2004.50

1Y change −95.02% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

HCWB HCW Biologics Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −19.75%
1 month: −43.75%
3 months: −72.00%
6 months: −39.31%
Year to date: −78.37%
1 year: −95.02%

Valuation & ownership

Market cap: 2.82M
Enterprise value: 8.13M
P/E (ttm): —
Forward P/E: -2.29
PEG ratio: —
Price / book: 0.27
Price / sales (ttm): 0.42
EV / EBITDA: -1.46
EPS (ttm): -19.84
EPS (forward): -0.5500
Beta (5y monthly): 2.42
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 2.24M
Float: 1.68M
Short % of float: 2.85%
Short ratio (days): 0.07
Held by insiders: 7.98%
Held by institutions: 7.41%
Avg volume (3m): 382.67K
50-day average: 2.42
200-day average: 4.54
52-week change: −95.02%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): oversold 26.4
vs 50-day SMA: −47.07%
vs 200-day SMA: −72.02%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 19.03%
Realised vol (20d, ann.): 102.0%
From 52-week high: −95.38%
From 52-week low: +0.80%

ANR

Analyst Consensus

1 analysts

Consensus

Buy

2.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

8.00

+534.92% implied

Low 8.00Median 8.00High 8.00

Recommendation trend

Now1 / 0 / 0

Buy / hold / sell counts

Financial Snapshot

Full statements →

DES

About HCW Biologics Inc.

Yahoo Finance profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 35
Headquarters: Miramar, FL, United States
Website: hcwbiologics.com
Officers: Dr. Hing C. Wong Ph.D. Founder, CEO, Director & Secretary
Ms. Rebecca Byam C.P.A., M.B.A. Chief Financial Officer

SEAS

Seasonality · HCWB

2021–2026 · monthly returns

Strongest month Feb +14.91%Weakest month Nov −22.59%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	14.3	-51.3	-33.5	30.8	320.4	-58.0	-35.9	12.2	-52.4	-26.3			−78.4%
2025	-37.7	36.7	-25.8	-28.5	-4.1	-48.7	6.9	34.9	-35.3	4.6	-45.2	-54.2	−94.6%
2024	-6.1	27.8	19.0	-20.0	-22.1	-40.6	-6.6	-23.7	16.9	-20.0	9.5	-5.5	−63.6%
2023	1.3	-7.2	-22.2	2.0	1.5	49.7	-6.0	-11.3	5.0	-11.6	-35.7	13.4	−36.0%
2022	-7.8	2.3	24.7	-14.3	-11.1	5.8	8.6	7.4	-10.8	-2.2	-5.8	-9.3	−17.5%
2021								-20.1	-19.6	40.1	-35.8	-19.2	−53.3%

INSD

Insider Activity · HCWB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 28, 2026	Garrett Scott TDirector	Purchase at price 2.58 per share.	7.7K	$20.00K
Jul 28, 2026	Wong Hing CChief Executive Officer	Purchase at price 2.58 per share.	23.2K	$60.00K
Jul 28, 2026	Flowers LeeOfficer	Purchase at price 2.58 per share.	7.7K	$20.00K
May 21, 2026	Garrett Scott TDirector	Purchase at price 2.89 per share.	177.9K	$514.24K
May 21, 2026	Wong Hing CChief Executive Officer	Purchase at price 2.89 per share.	113.9K	$329.11K
May 21, 2026	Byam RebeccaChief Financial Officer	Purchase at price 2.89 per share.	14.2K	$41.14K
May 15, 2025	Garrett Scott TDirector	Purchase at price 7.45 per share.	13.4K	$100.00K
May 15, 2025	Winer Gary MDirector	Purchase at price 7.45 per share.	1.3K	$10.00K
May 15, 2025	Wong Hing CChief Executive Officer	Purchase at price 7.45 per share.	8.1K	$60.00K
May 7, 2025	Garrett Scott TDirector	Purchase at price 7.15 per share.	5.4K	$38.50K
May 7, 2025	Greene Rick ScottDirector	Purchase at price 7.15 per share.	962	$6.88K
May 7, 2025	Winer Gary MDirector	Purchase at price 7.15 per share.	2.3K	$16.50K
May 7, 2025	Wong Hing CChief Executive Officer	Purchase at price 7.15 per share.	92.5K	$661.38K
May 7, 2025	Byam RebeccaChief Financial Officer	Purchase at price 7.15 per share.	8.5K	$60.50K
May 7, 2025	Flowers LeeOfficer	Purchase at price 7.15 per share.	962	$6.88K

HCWB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

HCWB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About HCW Biologics Inc.

Seasonality · HCWB

Insider Activity · HCWB

Congress Trades · HCWB

Investors Holding HCWB

Investors Holding HCWB

Congress Trades · HCWB

Insider Activity · HCWB

Seasonality · HCWB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About HCW Biologics Inc.

Earnings & Dividends

News